This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Aetiology and incidence

Authoring team

Aetiology and incidence

  • an estimated 5-7% of all people with psoriasis, and approximately 40% of those with extensive skin disease, have psoriatic arthritis (PsA)
  • undiagnosed PsA may be prevalent because many asymptomatic people with psoriasis have radiological evidence of joint damage
  • men and women are equally affected
  • because of problems in definitively diagnosing PsA, there are few studies on its incidence and prevalence, and the results vary widely depending on the cohort studied and the diagnostic criteria used
    • PsA has a prevalence of between 0.1% and 1% (1)
    • may develop at any age including childhood period (2)
    • incidence peaks between the ages of 30 and 55 years(1)
  • The condition has a genetic component:  
    • HLA-DR4 is a risk factor for psoriatic and rheumatoid arthritis
    • patients with psoriatic spondylitis share HLA-B27 with other spondylitic patients
    • the additional causal factors in psoriatic patients are unknown and may vary between patients

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.